Rare COVID Vaccine Clotting Linked to Adenoviral Protein  - Takeaway - MDSpire
Feature

Rare COVID Vaccine Clotting Linked to Adenoviral Protein 

Antibody proteomics and immunogenetics identify adenoviral protein VII as the trigger of PF4-targeting antibodies 

  • April 21, 2026

  • 2 min

Share

  • 1

    - VITT is linked to adenovirus-based COVID-19 vaccines. - The immune response targets platelet factor 4 (PF4). - Key immune trigger identified: adenoviral core protein VII (pVII). - Advanced techniques like mass spectrometry utilized in research. - Shared genetic mutation (K31E) found in anti-PF4 antibodies. - Future vaccines can be designed to avoid this reaction. - Researchers highlight need for further studies on vaccine safety. - Findings may influence future adenoviral vaccine design.

Original Source(s)

Rare COVID Vaccine Clotting Linked to Adenoviral Protein 

  • April 21, 2026

Related Content

Gene Therapy for Sickle Cell Could Be Cost-Effective in Uganda

New modeling study shows curative treatments may be viable in low-income settings if costs are scaled and societal benefits included

  • April 9, 2026

  • 2 min
Dynamic, Accessible Risk Stratification Tool Created for Smoldering Multiple Myeloma

Researchers have developed a dynamic risk stratification tool for patients with smoldering multiple myeloma to predict their chance of progression to active multiple myeloma. The tool, called Precurso...

ASH 2025: Myelofibrosis Roundup

For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being pa...